Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Randomised, Open-Label, Single and Multiple Ascending Dose (Twice-Daily), Incomplete Block, Cross-Over Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide Administered by Inhalation in Healthy Chinese Subjects

Trial Profile

A Phase I, Randomised, Open-Label, Single and Multiple Ascending Dose (Twice-Daily), Incomplete Block, Cross-Over Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide Administered by Inhalation in Healthy Chinese Subjects

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aclidinium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 28 Jul 2019 Planned End Date changed from 20 Sep 2019 to 16 Mar 2020.
    • 28 Jul 2019 Planned primary completion date changed from 20 Sep 2019 to 16 Mar 2020.
    • 28 Jul 2019 Planned initiation date changed from 23 Jul 2019 to 15 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top